MASCC oncodermatology clinical practice statement: prevention and management of acute radiation dermatitis with Mepitel Film and Hydrofilm.

[PURPOSE] Acute radiation dermatitis (ARD) is a frequent and burdensome complication of radiotherapy (RT), particularly in patients with breast and head and neck cancers. Film dressings, such as Mepitel Film and Hydrofilm, have emerged as effective prophylactic interventions for reducing ARD severity. This Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement (CPS) aims to provide practical, evidence-based guidance for the prevention and management of ARD using these film dressings.

[METHODS] The CPS was developed through a literature review and expert consensus within the MASCC Oncodermatology Study Group. Recommendations were formulated addressing key aspects of film dressing use, including patient selection, timing of application, skin preparation, dressing technique, product choice, and monitoring.

[RESULTS] Evidence from systematic review, network meta-analysis, and multiple RCTs indicates that Mepitel Film and Hydrofilm can significantly reduce the incidence and severity of ARD. Reduction is most prominent for moist desquamation in patients undergoing RT for breast and selected head and neck cancers. Practical guidance was established for identifying suitable patient groups, optimising application techniques, managing adherence challenges, and ensuring safe and effective use throughout the RT courses.

[CONCLUSION] Prophylactic use of Mepitel Film and Hydrofilm is recommended for reducing the severity of ARD in breast cancer and selected head and neck cancer patients. Clinical implementation should be individualised, considering anatomical factors, patient tolerance, and institutional resources.